11，Sollinger HW. Update on preclinical and clinical experience with mycop henolate mofetil. Transplantation Proceedings 1996,29 Suppl 1:24-29.
22，Groth CG. For the European MMF cooperative study group. The European e xperience with mycophenolate mofetil. Transplantation Proceedings 1996,28 Suppl 1:30-33.
35，Corna D, Morigi M, Facchinetti D, et al. Mycophenolate myfetil limit r enal damage and prolongs life in murin lupis autoimmune disease. Kidney Int 1997 ,51:1589-1589..
46，Willam A. Briggs, Michael J. Chor, Paul J. Scheel, Jr Successful mycop henolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998,31:213-2 17.
4Zhu P, Zhou FD, Wang SX, et al. Increasing frequency of idiopathic membranous nephropathy in primary glomerular disease:a 10 -year renal biopsy study from a single Chinese nephrology centre [ J ]. Nephrology (Carlton) ,2015,20(8) :560-566.
5Glassock RJ. Diagnosis and natural course of membranous nephropa- thy [ J ]. Semin Nephro1,2003,23 (4) :324 - 332.
6Tran TH, J Hughes G, Greenfeld C, et al. Overview of current and al- ternative therapies for idiopathie membranous nephropathy [ J ]. Pharmaeotherapy,2015,35 (4) :396 -411.
7Chen Y, Schieppati A, Chen X, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syn- drome[ J]. Cochrane Database Syst Rev,2014,10 : CD004293.
8Ponticelli C, Ahieri P, Scolari F, et al. A randomized study compa- ring methylprednisolone plus chlorambucil versus methylprednisolo- ne plus cyclophosphamide in idiopathic membranous nephropathy [ J ]. J Am Soe Nephrol, 1998,9 (3) :444 - 450.
9Yamaguchi M, Ando M, Yamamoto R, et al. Patient age and the prog- nosis of idiopathic membranous nephropathy[ J ]. PLoS One,2014,9 (10) :el 10376.
10Wang Y, Wang GP, Li BM, et al. Clinicopathological analysis of idio- pathic membranous nephropathy in young adults [ J ]. Genet Mol Res,2015,14(2) :4541 -4548.
